Competing interests: All authors have completed the ICMJE uniform disclosure form at www.icmje.org/disclosure-of-interest/ and declare: support from the Beijing Natural Science Foundation, National Natural Science Foundation of China, CAMS Innovation Fund for Medical Sciences, Non-profit Central Research Institute Fund of the Chinese Academy of Medical Sciences, and Training Program for Excellent Talents in Dongcheng District for the submitted work
Ozempic (semaglutide) and other glucagon-like peptide-1 (GLP-1) receptor agonist medications target underlying issues that drive weight gain during menopause, such as insulin resistance and metabolic shifts, explains endocrinologist and obesity specialist Alex Watson, M.D
You will receive ongoing support with unlimited messaging and follow-up visits
Microdosing GLP-1 Medications: a new trend in weight management
The BJP and its coalition partners will form a government that is a strong supporter of science in a broad sense, researchers say